High throughput screening for inhibition of cytochrome P450 metabolism

Medicinal Chemistry Research

Volumn 8, Issue 7-8, 1998, Pages 457-471

  Crespi, Charles L ^a   Miller, Vaughn P ^a   Penman, Bruce W ^a  

^a Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450; DICLOFENAC; ERYTHROMYCIN; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; PHENACETIN; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE; TRANYLCYPROMINE;

CONFERENCE PAPER; DECISION MAKING; DRUG INTERACTION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; ENZYME INHIBITION; ENZYME KINETICS; FOOD AND DRUG ADMINISTRATION; INHIBITION KINETICS; PROTEIN BINDING;

EID: 0032432731     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Burke MD Meyer RT. (1983). Differential effects of phenobartitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its O-alkoxy ethers. Chem. -Biol. Interact. 45, 243-258
2. Clarke SE, Ayrton AD, Chenery RJ. (1994). Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24, 517-526
3. Crespi CL, Miller VP, Penman BW. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Analyt. Biochem. 248, 188-190
4. Crespi CL and Penman BW. (1997). Use of cDNA-expressed human cytochrome P450 enzymes to study potential Drug-drug interactions. In: Li AP, ed. Drug-drug interactions, scientific and regulatory perspectives. San Diego: Academic Press, 171-188
5. PDA. (1997). Drug metabolism/drug interaction studies in the drug development process: Studies in vitro. Guide to Industry
6. Murray M. (1992). P450 Enzymes. Inhibition mechanism, genetic regulation and effects of liver disease. Clin. Pharmacokinet. 23, 132-146
7. Obach RS. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranalol. Drug Metab. Disp. 25, 1359-1369
8. Olkkola KT, Aranko K, Luurila H, Miller A, Saarmivaara L, Himberg JJ, Neuvonen PJ. (1993). A potentially hazardous interaction between erythromycin and midazolam. Clin. Pharmacol. Ther. 53, 298-305
9. Parkinson A. (1996). An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Path. 24, 45-57
10. 14C]-dextromethorphan. Analyt. Biochem. 219, 309-320
11. Rodrigues AD, Kukulka MJ, Roberts EM, Quellet D, Rodgers TR. (1996). (O-mehyl C-14)naproxen O-demethylase activity in human liver microsomes-evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metab. Disp. 24, 126-136
12. Rodrigues AD, Surber BW, Yao Y, Wong SL, Roberts EM. (1997). [O-Ethyl 14C]Phenacetin O-deethylase activity in human liver microsomes. Drug Metab. Disp. 25, 1097-1100
13. Spatzenegger M Jaeger W. (1995). Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab. Rev. 27, 397-417
14. White INH. (1988). A continuous assay for cytochrome P-450-dependent mixed function oxidases using 3-cyano-7-ethoxycoumarin. Analyt. Biochem. 172, 304-310
15. Wrighton SA Ring BJ. (1994). Inhibition of human CYP3A catalyzed 1′-hydroxylation of midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm. Res. 11, 921-924
16. Wynalda MA Wienkers LC. (1997). Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab. Disp. 25, 1211-1214